# Compass Pathways

于2026年2月宣布其COMP360合成裸盖菇素的第二项III期试验（COMP006）在难治性抑郁症方面达到主要终点，延续了其首次III期试验的积极结果。

Source: https://cn.bioecon.ru/companies/compass-pathways/
Updated: 2026-07-04

- 国家: United Kingdom
- 代码: CMPS

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 2026年2月完成$1.5亿融资，2026年报告认股权证行权$2亿，截至2024年10月报告的总融资额约为$9.487亿 | https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights/default.aspx, https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm |
| 产能 | 公司正致力于生产方法的可扩展性和商业可行性，并正在研究在美国增加商业化生产产能的可能性。 | https://content.edgar-online.com/ExternalLink/EDGAR/0001816590-26-000020.html?dest=cmps-20251231_htm&hash=4bd213ae6637fb8d386b1b55da9a9a90188198c6f222ab4ef4c87f6ffd588266 |
| 认证 | COMP360在治疗耐药性抑郁症方面获得美国FDA突破性疗法认定及英国创新许可与准入路径（ILAP）资格 | https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights/default.aspx, https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/, https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/, https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm |
| 监管批准 | 正在向美国FDA滚动提交并审查新药申请(NDA),最终提交预计于2026年第四季度完成;COMP360尚未获得上市批准 | https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights/default.aspx, https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/, https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm |
| 生产基地 | 该公司正在开发COMP360的生产工艺,但尚未明确指定用于商业化生产的具体生产基地 [中等置信度] | https://content.edgar-online.com/ExternalLink/EDGAR/0001816590-26-000020.html?dest=cmps-20251231_htm&hash=4bd213ae6637fb8d386b1b55da9a9a90188198c6f222ab4ef4c87f6ffd588266 |
| 员工人数 | 截至2025年12月31日有156名员工 | https://www.marketscreener.com/news/compass-pathways-2025-annual-report-ce7e50dddd8ff425 |
| 营收 | 公司披露的是净收入/净亏损而非营收;2026年第一季度净收入为$9120万,2026年上半年净亏损为$1.626亿 | https://s204.q4cdn.com/927483861/files/doc_news/Compass-Pathways-Announces-First-Quarter-2026-Financial-Results-and-Business-Highlights-2026.pdf, https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm |

独立来源: content.edgar-online.com, marketscreener.com, s204.q4cdn.com, sec.gov

## 技术

- [致幻剂医学与神经精神生物制剂](https://cn.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/)